The Medical Letter on Drugs and Therapeutics
- Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
- Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
- Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
- Drugs for Acute Otitis Media in Children
- Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
- Treatment of COVID-19 in High-Risk Outpatients (online only)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
February 7, 2022 (Issue: 1643)The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and...more
- Drugs for common eye disorders. Med Lett Drugs Ther 2019; 61:187.
- JA Katz et al. Presbyopia – a review of current treatment options and emerging therapies. Clin Ophthalmol 2021; 15:2167.
- JS Giyanani et al. Novel, fast-equilibrating, ophthalmic vehicle for enhanced patient comfort and tolerability for pilocarpine delivery. American Association of Pharmaceutical Scientists PharmSci 360 Meeting. October 26-November 5, 2020. Poster Abstract. Available at: https://bit.ly/3K5Q1V8. Accessed January 20, 2022.
- Approximate WAC for one 2.5-mL bottle. WAC = wholesaler acquisition cost, or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list prices and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.